CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and ...

CRISPR Therapeutics is poised to make meaningful strides in transforming the landscape of medicine," said CEO Samarth Kulkarni. "2025 stands as a milestone-rich year for CRISPR Therapeutics." ...

A high-speed crash in Chinchwad injured seven, including one critically, after a car hit three motorcycles. Driver Kulkarni faces charges.

Samarth Kulkarni, the Chief Executive Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), recently sold a significant portion of his holdings in the company, according to a recent SEC filing.

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as ...

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10 ...

Samarth Kulkarni, the Chief Executive Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), recently sold a significant portion of his holdings in the company, according ...